Member Info for travel_light

I can understand why health workers may have terms which reflect some of their reality. Ficking heroes the lot of em, and seeing death visit on a regular basis must require a certain language of defense.

For the rest of us, terms which imply deliberate action or in action which cost people lives reflects poorly on those who use such terms or think such action is acceptable. Unless of course it was meant to highlight such action as being undesirable.

People are more than stats, are more than a % gain, or a roll of the dice.

End of sermon but let’s try to keep some humanity even if we enjoy our investment. The company we own together will save lives, let’s use language to reflect that. I have to admit i am as guilty as the next man/woman.

apparently the Chancellor is upset about the cost, and wants clubs to be used next time. After all what did that generation ever do for the rest of us?

@gmcc thank you

raise, knew, and, go through

typing on phone and coffee needed:-)

I don’t think it was the razing of cash that’s the annoyance. More that a lot of people new prior including offer price, sold out whilst others were buying at 2 quid. Company was happy to see that happen and that might be AIM, c’est la vie. Still annoying thou.

I didn’t buy, had no cash and bought when it turned, so all good for me. Raising funds it what aim is about abd doing it effectively might mean PI miss out. That said price might hit offer price and synairgen today. Easier to buy on open market that go they hassle with dealer. On the other hand, ALL ABOARD ..... bloody great !

Lots of news this evening but this worth watching

could have done a right issue and rewarded existing share holders of course. Wonder if thats a question anyone set at the meeting last month with the Q and A section. Maybe keeping it quite and fairly private meant the price was higher, but on the open market shares where 2 quid. Rights issue at 1,60 would have gone down well, I'd have bought. No idea how much cost is associated with rights issue, maybe that's the reason why it wasn't offered.

if more money needed I'm happy to pay 1,20-

I feel like a four year old having to eat the fish paste sandwich before being allowed ice-cream:-)

I don't think company is forthcoming with as much info as they could be, but on this one we have been told Q4 for validation, Q1 before we see a test out in the wild. If nothing has changed I hope we will hear when tech transfer is complete. What else is there to know? Problems arise, problems get solved.

Yes company should focus on running the business. Funny how we find time to prepare presentations and speak to big US investors thou. Not the only company guilty of ignoring PI. Annual meetings are the time to voice those concerns. But most of us just along for the ride.

Doze, could be a sign of absolute confidence, not waste time with this Elisa test,LFD is cheaper, faster and better.

Only drawback is it’s not here. Could be huge confidence or just rolling the dice. Who knows? Errr insiders in the company, rest of us are crossing fingers:-) little harsh, Q1 is given timescale so I’ll trust that.

I dint get the impression that diagnostics seen as the golden goose, rather a stepping stone to the true calling of cancer treatments in a few years.

Would not surprise me to see diagnostics sold out, probably with cash + royalty deal. I think that will happen in less than 12 months. I have no evidence for that, just the same feeling as betting on a nag I like. It would make sense given the challenges of coming to market. Bigger company, more experience , better contacts, other conditions to test for that are already developed (lymes disease would be good). Etc etc

Given that LFD production is an issue and we (I’m an owner so yes we), can’t meet demand, why not raise more money by commercializing Elisa? Even if it’s not as good LFD will be limited capacity for a while, second wave is here. I guess at some point when it’s deemed a legal requirement we will be informed. Oh the joy:-)

I’ll stop the moaning about info flow now, put on my happy head. Amazing company, need to get operationally better, money in bank, big markets for years to come, good looking tech.

I like the idea of gaining value through demonstration of affimers. That is delivering value.

In terms of revenue I have no idea. PCR tests are bloody expensive and in short supply, this could fill that gap, and that is big money. Right now its worth nothing, despite huge demand globally for tests of any type. It's enough for Roche but then again they have path to market. Maybe Avacta cant bring this commercially to market as it's not just to take a credit card and send in the post. How to sell in, what does that channel look like, can it be done worldwide, who would do the selling, who to talk to, language constraints etc etc. As LFD coming along maybe they recognise that they are spread too thin, better to keep powder dry.

What I do see is some claiming on this BB that this is coming to market in a meaningful way. I am not convinced but open to being shown the light (please, no one happier than me if we can get €€€).

Rather than a demo, maybe they are waiting for someone with big distribution network to pick it up. But why not say so?

So here we are with a great test, but little in the way of info.

LTH in this, but the company could hardly be less informative and still stay legal. Major share holders in the company probably have good insight, and the II who got to buy in at 1,20 probably had a good run through the books and future. The rest of us have to trust our instincts and hope that the potential is met with an ability to execute. In normal companies news is not constant, normal companies do not operate with a pandemic as the major market place.

Yep, questions from the meeting last month not yet addressed. grrrrrrrrr :-D

Hi Timster,

thanks for taking time and effort. Appreciate it.

I am long on Avacta so before anyone loses their mind over a comment not deemed as 100% positive, take a breath, invest an appropriate amount of your capital, and try to use the power of group discussion to view a subject from many angles.

so at 30 seconds in Sir Al refers to the "reasearch" Elisa test. he continues to do this. I assume, that this is not a a test for diagnostics but only for researchers in universities etc. He specifically calls this test a research test, and that means something in terms of who can use it for what purpose. No public heath authority testing, and no detail of any plans.

7:30 he talks about performance of Elisa using same affimers and giving good indication for the LFD tests. No mention that elisa will be used to increase testing with public bodies.

compare to Roche RNS.

so why cant the Avacta Elisa test get a CE mark ? Does my reading of research mean something else? Maybe I missed something, and this will be a CE test.

At no point is it mentoien

whose Myles ?

bump, no one else commented this. amazing.

was going to post in that thread, but that would have been hi-jack.

For me the RNS from Roche was written well. It gave a timeline, it gave details about road to market and also throughput numbers. S+S would have been useful.

I have to admit I have lost track a little, have stopped wondering day to day. But Avacta Elisa test as far as I know is research only. We have no timeline said with any confidence for commercial, for that test or any of them. We have very little detail about route to market or even which markets will be targeted. The Roche RNS was way more informative.

The meeting nearly three weeks received a lot of questions and so far none have been answered. But Avacta meet with other investors in US, time is made for that.

I really like Avacta,string buy, but there is a huge amount of information floating around as rumour. We have people stating they know about tooling contracts, and others involved in certification etc

I can appreciate things are not always known, and things require confidentiality but if Roche can provide information, why can't Avacta ? But we own the company, many of us see this as long term holding. Information is available to share holders internally, and hell look at the placing with others knowing way before we did.

It would be nice to have this RNS format from Avacta for all the "inflection points". The vacuum gets filled with guesses and speculation otherwise, which might work for trading, but is pants for LTH.

anyway that's my moan, feel better for it:-)

Thanks for this.

Do we have this level of detail for the Avacta test?

What do we know, not assume or guess by “expert”but know?

RK

nice to see you back. Sorry to be picky, nice to be +ve and gung ho but nice to keep things simple also

Elisa at the mo is research only, hope that this will be commercial soon, will we sell direct or through partner do you think ?.
BAMS hope you are right and we get commercial deal done soon. Does anyone have news, BB very busy I might have missed it.
Wow LFD sales before end of year great, means Q1 date has moved up, awesome.

Phase II, great, I think you might mean phase I thou? Or that might be me getting my drug trial mixed up.

cheers TL

I’m so looking forward to the answers from the meeting in 28/9. Lots of information I hope.

I think for any organization with a trained nurse that Sona will be very attractive till a better test comes out. For those having to manage risk Avacta is not available and 0 info. Might be Q1 doesn’t cut it for sales in Q4.

My weighting is strongly in favor of Avacta , but sona might provide a nice pop to get extra sparkles on Xmas presents

I couldn’t net trade but needed to call my broker (with associated costs).

Looks a good short term play. Big demand for any test, and look like coming to market with Canadian order in the next few weeks. Long term not so sure.

Queensland is asking Townsville residents to get tested as covid detected in sewage.

Love the name Townsville.

Just shows that the idea is so useful. Can point to this as an example of why and value when selling. Also that Skin (old school) is not the only game in town. Hopefully more efficient and effective.

Source Guardian